Novo Nordisk and Eli Lilly have each filed their oral anti-obesity pills with South Korea's Ministry of Food and Drug Safety (MFDS), setting up a three-way competition in one of Asia's largest pharmaceutical markets once a locally developed injectable from Hanmi Pharmaceutical also reaches the finish line.
What Was Filed
Novo Nordisk submitted its oral semaglutide pill, marketed in the United States as the Wegovy Pill, while Eli Lilly filed Foundayo, its brand name for oral orforglipron. Both companies are seeking approval for weight management in South Korea, following the same regulatory playbook they used in the U.S. and other markets: establish the injectable franchise first, then bring an oral formulation to broaden access. If South Korea's review timeline tracks similar filings elsewhere, a decision and potential 2027 launch is plausible, though the MFDS sets its own review clock and timing is not guaranteed.
Why South Korea Is a Notable Test Case
South Korea gives both companies a market where a credible domestic competitor is also close to launching. Hanmi Pharmaceutical, a Korean drugmaker, has run Phase 3 trials of its injectable candidate, internally referred to as EPPE, in Korean patients specifically, and local media have reported the company is targeting approval around October 2026 with a commercial launch by year-end. That domestic trial data, run in a Korean population rather than extrapolated from Western trials, is a genuine advantage Hanmi is leaning on.
How the Three Candidates Differ
The two multinational filings are not mechanistically identical. Novo Nordisk's Wegovy Pill is a peptide formulated for oral absorption, which is why it needs to be taken on an empty stomach with a small amount of water and requires a 30-minute wait before eating or taking other medications. Foundayo is a small-molecule GLP-1 receptor agonist rather than a peptide, which Lilly has marketed as an advantage because it does not require food or water restrictions and can be taken more flexibly. Hanmi's EPPE, by contrast, is an injectable, trading the convenience of a pill for a different administration route and, according to reported Phase 3 data from a 448-patient Korean trial, an average weight reduction around 9.75% after 40 weeks, a smaller figure than the headline results Novo Nordisk and Lilly have reported for their own candidates in other populations and trial designs, which are not directly comparable without a head-to-head study.
Pricing Context
Pricing is likely to be a major factor in how this competition plays out. In the U.S., both oral formulations launched around $149 per month, a steep discount versus the roughly $1,000 list price of their injectable counterparts. Hanmi has reportedly targeted a price near â‚©100,000 (about $72) for a four-week supply of EPPE domestically. None of these figures directly predict Korean pricing for the Novo Nordisk or Lilly pills, which will depend on MFDS approval terms and separate reimbursement negotiations, but the price gap between the injectable incumbents and the newer oral and domestic options is already shaping the competitive narrative.
What Happens Next
Both multinational filings now sit with Korean regulators, and there is no public commitment from either company to a specific approval date. Hanmi's domestic timeline is reportedly further along. None of this changes the FDA-approval status of these drugs in the United States, where oral semaglutide and oral orforglipron are already approved for weight management; this filing is specifically about expanding availability into the South Korean market.
The Bottom Line
This is a regulatory filing, not an approval, and the practical effect for patients outside South Korea is minimal. But it's a useful marker of how the oral GLP-1 category is expanding market by market, and of how a capable domestic manufacturer with local trial data can credibly compete with the two companies that currently dominate the global obesity drug market.